Mark C Genovese
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
Burmester G, Boklage S, St John G, Thangavelu K, Gervitz L, Pena-Rossi C, Gómez-Centeno A, Raskina T, Amital H, Rubbert-Roth A, Strand V, Genovese M. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. RMD Open 2019; 5:e001017.
Oct 18, 2019Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
Oct 18, 2019RMD Open 2019; 5:e001017
Burmester Gerd R, Boklage Susan, St John Gregory, Thangavelu Karthinathan, Gervitz Leon, Pena-Rossi Claudia, Gómez-Centeno Antonio, Raskina Tatiana, Amital Howard, Rubbert-Roth Andrea, Strand Vibeke, Genovese Mark C
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Genovese M, Meerwein S, Mohamed M, Zhou Y, Zhang Y, Rubbert-Roth A, Hall S, Combe B, Fleischmann R, Pangan A. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 2018; 391:2513-2524.
Jun 18, 2018Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Jun 18, 2018Lancet 2018; 391:2513-2524
Genovese Mark C, Meerwein Sebastian, Mohamed Mohamed-Eslam F, Zhou Yijie, Zhang Ying, Rubbert-Roth Andrea, Hall Stephen, Combe Bernard, Fleischmann Roy, Pangan Aileen L